Jane Perlmutter
Overview
Explore the profile of Jane Perlmutter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
5532
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Basch E, Schrag D, Jansen J, Henson S, Ginos B, Stover A, et al.
Nat Med
. 2025 Feb;
PMID: 39920394
Symptoms are often underdetected during cancer treatment. To determine if symptom monitoring with electronic patient-reported outcomes (PROs) improves clinical outcomes, we conducted a cluster-randomized trial in which 52 oncology practices...
2.
Rugo H, Campbell M, Yau C, Jo Chien A, Wallace A, Isaacs C, et al.
Breast Cancer Res Treat
. 2024 Dec;
209(3):487-492.
PMID: 39625569
Purpose: We investigated the small-molecule receptor tyrosine kinase-inhibitor of colony-stimulating factor-1 receptor pexidartinib in the stage II/III breast cancer in the I-SPY2 platform trial. Methods: I-SPY2 is an adaptive platform...
3.
Campbell M, Wolf D, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher I, et al.
Cell Rep Med
. 2024 Nov;
5(11):101799.
PMID: 39510069
Only a subset of patients with breast cancer responds to immune checkpoint blockade (ICB). To better understand the underlying mechanisms, we analyze pretreatment biopsies from patients in the I-SPY 2...
4.
Shatsky R, Trivedi M, Yau C, Nanda R, Rugo H, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3737-3747.
PMID: 39277672
Sequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity. Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan...
5.
Khoury K, Meisel J, Yau C, Rugo H, Nanda R, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3728-3736.
PMID: 39277671
Among the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer...
6.
Magbanua M, Ahmed Z, Sayaman R, Swigart L, Hirst G, Yau C, et al.
Clin Cancer Res
. 2024 Mar;
30(11):2444-2451.
PMID: 38470545
Purpose: We previously demonstrated the clinical significance of circulating tumor DNA (ctDNA) in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy (NAC). Here, we compared its predictive and prognostic value...
7.
Albain K, Yau C, Petricoin E, Wolf D, Lang J, Jo Chien A, et al.
Clin Cancer Res
. 2023 Dec;
30(4):729-740.
PMID: 38109213
Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients...
8.
Gallagher R, Wulfkuhle J, Wolf D, Brown-Swigart L, Yau C, OGrady N, et al.
Cell Rep Med
. 2023 Dec;
4(12):101312.
PMID: 38086377
Molecular subtyping of breast cancer is based mostly on HR/HER2 and gene expression-based immune, DNA repair deficiency, and luminal signatures. We extend this description via functional protein pathway activation mapping...
9.
Chakraborty M, Hill R, Corbin K, Perlmutter J, Wright J, Choi J
Ann Palliat Med
. 2023 Nov;
12(6):1469-1474.
PMID: 37953215
No abstract available.
10.
Hillman S, Jatoi A, Strand C, Perlmutter J, George S, Mandrekar S
JAMA Oncol
. 2023 Jun;
9(8):1041-1047.
PMID: 37347469
Importance: Patient withdrawal of consent from a cancer clinical trial is defined as a patient's volitional cessation of participation in all matters related to a trial. It can undermine the...